The AIP Knouckout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung carcinoma cell line, featuring targeted disruption of the AIP (aryl hydrocarbon receptor interacting protein) gene. This loss-of-function model is generated using CRISPR/Cas9-mediated gene disruption, resulting in a heterogeneous pool of cells with abrogated AIP expression, enabling the study of AIP-dependent signaling pathways in a lung cancer background without the biases introduced by clonal selection.
A-549 cells are a well-characterized human lung adenocarcinoma cell line originally established from a 58-year-old male patient. These cells display features of alveolar type II-like epithelial cells and serve as a robust in vitro model for investigating lung adenocarcinoma biology, xenobiotic metabolism, and epithelial cell signaling. Their expression of functional aryl hydrocarbon receptor (AhR) signaling components and intact cAMP/PKA pathway machinery makes them particularly suitable for interrogating the molecular functions of AIP.
AIP functions as a co-chaperone for AhR, forming a cytoplasmic complex with Hsp90 that stabilizes the receptor in a ligand-binding competent state. Upon activation by AhR agonists such as TCDD or benzo[a]pyrene, AhR undergoes conformational changes, dissociates from the complex, and translocates to the nucleus where it dimerizes with ARNT (HIF-1??) to transcriptionally regulate target genes including CYP1A1, CYP1B1, AHRR, and TIPARP. AIP also interacts with other Hsp90 client proteins, HSP70, FKBP52, and phosphodiesterase 4A5 (PDE4A5), and has been implicated in modulating cAMP/PKA signaling through its interaction with PDE4A5. Disruption of AIP therefore impairs AhR-dependent xenobiotic response and may deregulate cell cycle progression via altered expression of CDKN1B.
In the A-549 lung carcinoma context, loss of AIP provides a valuable tool for dissecting the non-endocrine roles of this co-chaperone. While AIP mutations are primarily associated with familial isolated pituitary adenomas (FIPA) and related somatotropinomas or prolactinomas, A-549 cells allow exploration of AIP’s function in lung-derived epithelial cells where AhR signaling influences xenobiotic metabolism and potentially tumorigenesis. The knockout model facilitates investigation into how AIP deficiency alters the cellular response to environmental carcinogens, cAMP-mediated signal transduction, and growth control pathways relevant to lung cancer biology.
Researchers can employ this polyclonal knockout cell population for a variety of experimental applications including quantitative analysis of AhR pathway activity using CYP1A1 induction assays (by RT-qPCR), AhR luciferase reporter systems, and co-immunoprecipitation studies to probe AIP-AhR-Hsp90 complex assembly. Additional uses encompass cAMP measurement assays, cell viability and proliferation studies, and drug screening efforts aimed at endocrine tumor therapeutics. The polyclonal nature provides a more representative population-average knockout effect compared to single clones. For further information or to request these cells, please contact Ascent Research.
